Search Results - Michael A. Davies

Refine Results
  1. 1
    Analysis of the genome to personalize therapy for melanoma

    Analysis of the genome to personalize therapy for melanoma by Michael A. Davies, Yardena Samuels

    Published 2010
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Targeted therapy for melanoma: rational combinatorial approaches

    Targeted therapy for melanoma: rational combinatorial approaches by Lawrence N. Kwong, Michael A. Davies

    Published 2013
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics

    Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics by Scott E. Woodman, Michael A. Davies

    Published 2010
    Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma

    Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma by Lawrence N. Kwong, Michael A. Davies

    Published 2013
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Melanoma Brain Metastases

    Melanoma Brain Metastases by Isabella Glitza Oliva, Hussein A. Tawbi, Michael A. Davies

    Published 2017
    Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    New Strategies in Melanoma: Molecular Testing in Advanced Disease

    New Strategies in Melanoma: Molecular Testing in Advanced Disease by Scott E. Woodman, Alexander J. Lazar, Kenneth Aldape, Michael A. Davies

    Published 2012
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  7. 7
    <scp>RAC</scp>1 P29S regulates <scp>PD</scp>‐L1 expression in melanoma

    <scp>RAC</scp>1 P29S regulates <scp>PD</scp>‐L1 expression in melanoma by Ha Linh Vu, Sheera R. Rosenbaum, Timothy J. Purwin, Michael A. Davies, Andrew E. Aplin

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor

    Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor by Curtis H. Kugel, Edward J. Hartsough, Michael A. Davies, Yulius Y. Setiady, Andrew E. Aplin

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells

    MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells by Motoyoshi Tanaka, Dimpy Koul, Michael A. Davies, Monica Liebert, Peter A. Steck, H. Barton Grossman

    Published 2000
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties

    ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties by Merrida Childress, Stephen M. Himmelberg, Huiqin Chen, Wanleng Deng, Michael A. Davies, Christine M. Lovly

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in <i>Braf-</i>Mutant Human Cutaneous Melanoma Cells

    Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in <i>Braf-</i>Mutant Human Cutaneous Melanoma Cells by Y.N. Vashisht Gopal, Wanleng Deng, Scott E. Woodman, Kakajan Komurov, Prahlad T. Ram, Paul D. Smith, Michael A. Davies

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Pathways and therapeutic targets in melanoma

    Pathways and therapeutic targets in melanoma by Emma Shtivelman, Michael A. Davies, Patrick Hwu, James C. Yang, Michal Lotem, Moshe Oren, Keith T. Flaherty, David E. Fisher

    Published 2014
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  13. 13
    Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant <i>GNAQ-</i> and <i>GNA11</i>-Dependent Manner

    Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant <i>GNAQ-</i> and <i>GNA11</i>-Dependent Manner by Jahan S. Khalili, Xiaoxing Yu, Ji Wang, Brendan C. Hayes, Michael A. Davies, Gregory Lizée, Bita Esmaeli, Scott E. Woodman

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications

    Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications by Grant M. Fischer, Y.N. Vashisht Gopal, Jennifer L. McQuade, Weiyi Peng, Ralph J. DeBerardinis, Michael A. Davies

    Published 2017
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  15. 15
    Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma

    Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma by Hanyin Cheng, Vivian Chua, Connie Liao, Timothy J. Purwin, Mizue Terai, Ken Kageyama, Michael A. Davies, Takami Sato, Andrew E. Aplin

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Body mass index and survival after cancer diagnosis: A pan-cancer cohort study of 114 430 patients with cancer

    Body mass index and survival after cancer diagnosis: A pan-cancer cohort study of 114 430 patients with cancer by Huakang Tu, Jennifer L. McQuade, Michael A. Davies, Maosheng Huang, Kunlin Xie, Yuanqing Ye, Wong‐Ho Chow, Maria Alma Rodriguez, Xifeng Wu

    Published 2022
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    A novel AKT3 mutation in melanoma tumours and cell lines

    A novel AKT3 mutation in melanoma tumours and cell lines by Michael A. Davies, Katherine Stemke‐Hale, Carmen S. Tellez, Tiffany L. Calderone, Wuguo Deng, Víctor G. Prieto, Alexander J. Lazar, Jeffrey E. Gershenwald, Gordon B. Mills

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma

    Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma by Saadia A. Aziz, Michael A. Davies, Elah Pick, Christopher R. Zito, Lucia B. Jilaveanu, Robert L. Camp, David L. Rimm, Yuval Kluger, Harriet M. Kluger

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrow–Resident Melanoma CTCs

    Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrow–Resident Melanoma CTCs by Monika Vishnoi, Debasish Boral, Haowen Liu, Marc L. Sprouse, Wei Yin, Debalina Goswami-Sewell, Michael T. Tetzlaff, Michael A. Davies, Isabella C. Glitza Oliva, Philippe Marchetti

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series

    Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series by K. Holbrook, Jose Lutzky, Michael A. Davies, Jessica Davis, Isabella C. Glitza, Rodabe N. Amaria, Adi Diab, Sapna P. Patel, Asim Amin, Hussein A. Tawbi

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: